Galectin-3: clinical utility and prognostic value in patients with heart failure
Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available abo...
Main Author: | Kramer F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-02-01
|
Series: | Research Reports in Clinical Cardiology |
Online Access: | http://www.dovepress.com/galectin-3-clinical-utility-and-prognostic-value-in-patients-with-hear-a12144 |
Similar Items
-
Prognostic Value of Galectin-3 in Patients with Heart Failure
by: Ivica Bošnjak, et al.
Published: (2015-01-01) -
CLINICAL VALUE OF DETERMINING GALECTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE
by: K. A. Gyamdzhyan, et al.
Published: (2017-12-01) -
Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure.
by: Julio Núñez, et al.
Published: (2015-01-01) -
PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 LEVEL ASSESSMENT IN METABOLIC SYNDROME PATIENTS WITH HEART FAILURE
by: O. M. Drapkina, et al.
Published: (2017-12-01) -
The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
by: François Koukoui, et al.
Published: (2015-01-01)